Biophytis: Invest Securities raises its recommendation

(CercleFinance.com) - Invest Securities has raised its recommendation on Biophytis from 'neutral' to 'buy' on the back of the 'buoyant momentum surrounding GLP-1', while lowering its target price from 2.
21 to 0.82 euros, given that the company recently raised up to 8.6 million euros.

The research firm points out that Biophytis intends to evaluate the benefits of combining its BIO101 with GLP-1s, which are used to treat obesity but are known to induce a loss of muscle mass of up to 40% of the total weight lost.

In certain obese subjects whose muscles are already weakened, additional muscle loss can tip them into sarcopenia and a disabling situation", points out the analyst, noting that a Phase II trial is due to be initiated shortly.

Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.